Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
bluebird bio, Inc. (NASDAQ:BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with be...
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Sunday, 8th December at 12:30 pm
Stable production of anti-sickling adult hemoglobin (HBAT87Q) and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients (n=38), underscoring potentially transforma...
$Roth CH Acquisition V Co (ROCL.US)$ Ticker change tomorr...
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Saturday, 7th December at 12:00 pm
Treatment effects sustained through long-term follow-up of beyond 10 years in the earliest treated patients (n=2); 81% of participants have >5 years of follow-up
bluebird bio,...
Pfizer presents P3 data at ASH next week December 9th
And Fabry deal discussions are well underway after getting Acellerated Approval from FDA recently. A couple of nice near term catalysts that should move the stock.
No comment yet